Transforming growth factor-beta and its implication in the malignancy of gliomas

Targeted Oncology

Volumn 10, Issue 1, 2015, Pages

  Roy, Laurent Olivier ^a   Poirier, Marie Belle ^a   Fortin, David ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Glioblastoma; Malignancy development; Migration and invasion; Targeted therapy; Transforming growth factor

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

BRAIN TUMOR; GENETICS; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BRAIN NEOPLASMS; GLIOMA; HUMANS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84894599363     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0308-y     Document Type: Review

References (139)

1. Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358
2. Govinden R, Bhoola KD (2003) Genealogy, expression, and cellular function of transforming growth factor-b. Pharmacol Ther 98:257–265
3. Wang G, Matsuura I, He D et al (2009) Transforming growth factor-{beta}-inducible phosphorylation of Smad3. J Biol Chem 284:9663–9673
4. Wakefield LM, Roberts AB (2002) TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12:22–29
5. Dolecek TA, Propp JM, Stroup NE et al (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neurol Oncol 14:v1–49
6. Jiang Y, Uhrbom L (2012) On the origin of glioma. Ups J Med Sci 117:113–121
7. Liu C, Sage JC, Miller MR et al (2011) Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146:209–221
8. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812
9. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
10. Bao S, Wu Q, McLendon RE et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760
11. Beier D, Schulz JB, Beier CP (2011) Chemoresistance of glioblastoma cancer stem cells—much more complex than expected. Mol Cancer 10:128
12. Bleau A-M, Hambardzumyan D, Ozawa T et al (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4:226–235
13. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
14. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A et al (2010) TGF-beta receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell 18:655–668
15. Desmarais G, Fortin D, Bujold R et al (2012) Infiltration of glioma cells in brain parenchyma stimulated by radiation in the F98/Fischer rat model. Int J Radiat Biol 88:565–574
16. Kjellman C, Olofsson S, Hansson O (2000) Expression of TGF-β isoforms, TGF-β receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89:251–258
17. Gatherer D, Ten Dijke P, Baird DT et al (1990) Expression of TGF-beta isoforms during first trimester human embryogenesis. Development 110:445–460
18. Saharinen J, Hyytiäinen M, Taipale J et al (1999) Latent transforming growth factor-beta binding proteins (LTBPs)—structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 10:99–117
19. Dubois CM, Laprise M-H, Blanchette F et al (1995) Processing of transforming growth factor b1 precusor by human furin convertase. J Biol Chem 270:10618–10624
20. Clark DA, Coker R (1998) Transforming growth factor-beta (TGF-b). Int J Biochem Cell Biol 30:293–298
21. Horimoto M, Kato J, Takimoto R et al (1995) Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line. Br J Cancer 72:676–682
22. Kaminska B, Wesolowska A, Danilkiewicz M (2005) TGF beta signaling and its role in tumour pathogenesis. Acta Biochim Pol 52:329–337
23. Gatza CE, Oh SY, Blobe GC (2010) Roles for the type III TGF-beta receptor in human cancer. Cell Signal 22:1163–1174
24. Massagué J, Wotton D (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19:1745–1754
25. Huang T, David L, Mendoza V et al (2011) TGF-beta; signaling is mediated by two autonomously functioning TBRI:TBRII pairs. EMBO J 30:1263–1276
26. Massagué J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295–309
27. Xu J (2000) Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor β signaling by targeting Smads to the ubiquitin–proteasome pathway. Paper presented at the Proc Natl Acad Sci U S A
28. Abdollah S, Marcias-Silva M, Tsukazaki T et al (1997) TBRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and. J Biol Chem 272:27678–27685
29. Matsuura I, Denissova NG, Wang G et al (2004) Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430:226–231
30. Tsukazaki T, Chiang T, Davison A et al (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGF [beta] receptor. Cell 95:779–791
31. Hayashi H, Abdollah S, Qiu Y et al (1997) The MAD-related protein Smad7 associates with the TGFB receptor and functions as an antagonist of TGFB signaling. Cell 89:1165–1173
32. Nakao A, Imamura T, Souchelnytskyi S et al (1997) TGF-beta receptor-mediated signaling through Smad2, Smad3 and Smad4. EMBO J 16:5353–5362
33. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425:577–584
34. Ebisawa T, Fukuchi M, Murakami G (2001) Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276:12477–12480
35. Kavsak P, Rasmussen RK, Causing CG et al (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation. Mol Cell 6:1365–1375
36. Lin X (2000) Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 275:36818–36822
37. Morén A, Imamura T, Miyazono K et al (2005) Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J Biol Chem 280:22115–22123
38. Inui M, Manfrin A, Mamidi A et al (2011) USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell Biol 13:1368–1375
39. Aggarwal K, Massagué J (2012) Ubiquitin removal in the TGF-β pathway. Nat Cell Biol 14:656–657
40. De Boeck M, Ten Dijke P (2012) Key role for ubiquitin protein modification in TGFβ signal transduction. Ups J Med Sci 117:153–165
41. Dupont S, Mamidi A, Cordenonsi M et al (2009) FAM/USP9x, a deubiquitinating enzyme essential for TGFβ signaling, controls Smad4 monoubiquitination. Cell 136:123–135
42. Eichhorn PJA, Rodón L, Gonzàlez-Juncà A et al (2012) USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat Med 18:429–435
43. Zhang L, Zhou F, Drabsch Y et al (2012) USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat Cell Biol 14:717–726
44. Moustakas A, Heldin C-H (2005) Non-Smad TGF-β signals. J Cell Sci 118:3573–3584
45. Mu Y, Gudey SK, Landström M (2011) Non-Smad signaling pathways. Cell Tissue Res 347:11–20
46. Zhang YE (2009) Non-Smad pathways in TGF-β signaling. Cell Res 19:128–139
47. Chen R, Ebner R (1993) Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science 260:1335–1338
48. Jennings MT, Pietenpol JA (1998) The role of transforming growth factor beta in glioma progression. J Neurooncol 36:123–140
49. Galli R, Binda E, Orfanelli U et al (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021
50. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
51. Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401
52. Turner JD, Abla AA, Sanai N (2012) Identification of the glioma cell of origin. World Neurosurg, Sep, pp 200-201
53. Gomez GG, Kruse CA (2006) Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 10:133–146
54. Fortin D, Desjardins A, Benko A et al (2005) Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors. Cancer 103:2606–2615
55. Bigner SH, Mark J, Bullard DE et al (1986) Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations. Cancer Genet Cytogenet 22:121–135
56. Bigner SH, Mark J, Burger PC et al (1988) Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 48:405–411
57. Gadji M, Fortin D, Tsanaclis AM et al (2010) Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients. Neoplasia 12:183–191
58. Louis SF, Vermolen BJ, Garini Y et al (2005) c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci U S A 102:9613–9618
59. Rasheed BK, Wiltshire RN, Bigner SH et al (1999) Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 11:162–167
60. Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430–446
61. Constam DB, Philipp J, Malipiero UV et al (1992) Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148:1404–1410
62. Schneider T, Sailer M, Ansorge S et al (2006) Increased concentrations of transforming growth factor β1 and β2 in the plasma of patients with glioblastoma. J Neurooncol 79:61–65
63. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A et al (2006) Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev 17:129–139
64. Gomez GG, Varella-Garcia M, Kruse CA (2006) Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization. Cancer Genet Cytogenet 165:121–134
65. Lassman AB, Dai C, Fuller GN et al (2004) Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biol 1:157–163
66. Ikushima H, Todo T, Ino Y et al (2009) Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Stem Cell 5:504–514
67. Seoane J, Le H-V, Shen L et al (2004) Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117:211–223
68. Bruna A, Darken RS, Rojo F et al (2007) High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11:147–160
69. Song L, Liu L, Wu Z et al (2012) TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. J Clin Invest 122:3563–3578
70. Frank SA, Nowak MA (2003) Cell biology: developmental predisposition to cancer. Nature 422:494
71. Günther HS, Schmidt NO, Phillips HS et al (2007) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:2897–2909
72. Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828
73. Frosina G (2009) DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 7:989–999
74. Godlewski J, Nowicki MO, Bronisz A et al (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68:9125–9130
75. Molofsky AV, Pardal R, Iwashita T et al (2003) Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425:962–967
76. Peñuelas S, Anido J, Prieto-SAnchez RM et al (2009) TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15:315–327
77. Bauer S, Patterson PH (2006) Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J Neurosci 26:12089–12099
78. Bonni A (1997) Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 278:477–483
79. Nam H-s, Benezra R (2009) High levels of Id1 expression define B1 type adult neural stem cells. Stem Cell 5:515–526
80. Clarke MF, Dick JE, Dirks PB et al (2006) Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339–9344
81. Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173
82. Marchetto MCN, Carromeu C, Acab A et al (2010) A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143:527–539
83. Tonn JC, Kerkau S, Hanke A et al (1999) Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer 80:764–772
84. Rooprai HK, Rucklidge GJ, Panou C et al (2000) The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br J Cancer 82:52–55
85. Uhm JH, Gladson CL, Rao JS (1999) The role of integrins in the malignant phenotype of gliomas. Front Biosci 4:D188–199
86. Wick W, Platten M, Weller M (2001) Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53:177–185
87. Huijbers IJ, Iravani M, Popov S et al (2010) A role for fibrillar collagen deposition and the collagen internalization receptor Endo180 in glioma invasion. PLoS ONE 5:e9808
88. Chung AS, Lee J, Ferrara N (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10:505–514
89. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31
90. Jensen RL (1998) Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 49:189–195
91. Pepper M (1997) Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8:21–43
92. Plate K, Breier G, Weich H (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848
93. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447
94. Kavanaugh W, Harsh G, Starksen N (1988) Transcriptional regulation of the A and B chain genes of platelet-derived growth factor in microvascular endothelial cells. J Biol Chem 263:8470–8472
95. Tsai JC, Goldman CK, Gillespie GY (1995) Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 82:864–873
96. Wang D, Huang HJ, Kazlauskas A et al (1999) Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 59:1464–1472
97. Platten M, Wick W, Weller M (2001) Malignant glioma biology: role for TGF-β in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52:401–410
98. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 14:163–176
99. Pardridge WM (2007) Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J Control Release 122:345–348
100. Rubin LL, Staddon JM (1999) The cell biology of the blood-brain barrier. Annu Rev Neurosci 22:11–28
101. Hickey WF (2001) Basic principles of immunological surveillance of the normal central nervous system. Glia 36:118–124
102. Walker PR, Calzascia T, Dietrich PY (2002) All in the head: obstacles for immune rejection of brain tumours. Immunology 107:28–38
103. Quattrocchi KB, Miller CH, Cush S et al (1999) Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45:141–157
104. Brooks WH, Roszman TL, Mahaley MS et al (1977) Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin Exp Immunol 29:61–66
105. Dix AR, Brooks WH, Roszman TL et al (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100:216–232
106. Lowin-Kropf B, Shapiro VS, Weiss A (1998) Cytoskeletal polarization of T cells is regulated by an immunoreceptor tyrosine-based activation motif-dependent mechanism. J Cell Biol 140:861–871
107. Woiciechowsky C, Asadullah K, Nestler D et al (1998) Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation. J Neuroimmunol 84:164–171
108. Morford LA, Elliott LH, Carlson SL et al (1997) T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159:4415–4425
109. Smyth M, Strobl S, Young H (1991) Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-b1. J Immunol 146:3289–3297
110. Crane CA, Han SJ, Barry JJ et al (2010) TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 12:7–13
111. Friese MA, Wischhusen J, Wick W et al (2004) RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64:7596–7603
112. Ahuja S, Paliogianni F, Yamada H (1993) Effect of transforming growth factor-beta on early and late activation events in human T cells. J Immunol 150:3109–3118
113. Brooks B, Chapman K, Lawry J et al (1990) Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production. Clin Exp Immunol 82:583–589
114. Arteaga C, Hurd S, Winnier A (1993) Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J Clin Invest 92:2569–2576
115. Inge T, Hoover S, Susskind B et al (1992) Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β1. Cancer Res 52:1386–1392
116. Suzumura A, Sawada M (1993) Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol 151:2150–2158
117. Facoetti A, Pasi F, Nano R (2010) Some considerations for the study of TGFbeta in medium of irradiated T98G cells: activation, release and consumption. Anticancer Res 30:3341–3344
118. Gow MD, Seymour CB, Ryan LA et al (2010) Induction of bystander response in human glioma cells using high-energy electrons: a role for TGF-beta1. Radiat Res 173:769–778
119. Zhang M, Kleber S, Röhrich M et al (2011) Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71:7155–7167
120. Hardee ME, Marciscano AE, Medina-Ramirez CM et al (2012) Resistance of glioblastoma initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β (TGFβ). Cancer Res 72:4119–4129
121. Sims JT, Ganguly SS, Bennett H et al (2013) Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS ONE 8:e55509
122. Zhang M, Herion TW, Timke C et al (2011) Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia 13:537–549
123. Fakhrai H, Dorigo O, Shawler DL et al (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 93:2909–2914
124. Hau P, Jachimczak P, Schlingensiepen R et al (2007) Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17:201–212
125. Bogdahn U, Hau P, Stockhammer G et al (2011) Targeted therapy for high-grade glioma with the tgf-β2 inhibitor trabedersen: results of a randomized and controlled phase iib study. Neuro Oncol 13:132–142
126. Basque J, Martel M, Leduc R et al (2008) Lysosomotropic drugs inhibit maturation of transforming growth factor-β. Can J Physiol Pharmacol 86:606–612
127. Ya Y (2002) Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109:1607–1615
128. Ueda R, Fujita M, Zhu X et al (2009) Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 15:6551–6559
129. Thomas G (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3:753–766
130. DaCosta BS, Major C, Laping N (2004) SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 65:744–752
131. Uhl M, Aulwurm S, Wischhusen J et al (2004) SD-208, a novel transforming growth factor receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64:7954–7961
132. Schlingensiepen R, Goldbrunner M, Szyrach MNI et al (2005) Intracerebral and intrathecal iof the TGF-β2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 15:94–104
133. Fortin D (2012) The blood-brain barrier: its influence in the treatment of brain tumors metastases. Curr Cancer Drug Targets 12:247–259
134. Newton HB, Slivka MA, Volpi C et al (2003) Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neurooncol 61:35–44
135. De Jong WH, Borm PJ (2008) Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 3:133–149
136. Wilczewska AZ, Niemirowicz K, Markiewicz KH et al (2012) Nanoparticles as drug delivery systems. Pharmacol Rep 64:1020–1037
137. Hösli P, Sappino AP, de Tribolet N et al (1998) Malignant glioma: should chemotherapy be overthrown by experimental treatments? Ann Oncol 9:589–600
138. Silbergeld DL, Chicoine MR (1997) Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86:525–531
139. Veilleux N, Goffaux P, Boudrias M et al (2010) Quality of life in neurooncology—age matters. J Neurosurg 113:325–332